Oric Pharmaceuticals
ORIC
152 hedge funds and large institutions have $1.28B invested in Oric Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 58 increasing their positions, 34 reducing their positions, and 22 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 34
45% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 22
35% more capital invested
Capital invested by funds: $948M → $1.28B (+$330M)
7% more funds holding
Funds holding: 142 → 152 (+10)
0.1% more ownership
Funds ownership: 109.55% → 109.65% (+0.1%)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
79% less call options, than puts
Call options by funds: $447K | Put options by funds: $2.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$53.8M |
| 2 |
O
OrbiMed
New York
|
+$28.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16M |
| 4 |
RA
Royce & Associates
New York
|
+$12.9M |
| 5 |
BlackRock
New York
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$10.8M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$4.93M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
-$3.68M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.72M |
| 5 |
SCM
Superstring Capital Management
New York
|
-$2.69M |
ORIC Hedge Fund Activity: Q3 2025 in Review
152 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q3 2025, worth a combined $1.28B — up 35% from $948M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ORIC positions and 22 closed out — a net gain of 10 holders — while 58 added to existing stakes and 34 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $53.8M. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $10.8M sold.
- 152 institutional investors held Oric Pharmaceuticals (ORIC) as of Q3 2025, up from 142 in Q2 2025.
- Funds reported $1.28B of Oric Pharmaceuticals stock for Q3 2025, up 35% quarter-over-quarter.
- 32 funds opened new Oric Pharmaceuticals positions in Q3 2025 and 22 closed out, a net change of +10 holders.
- The largest Oric Pharmaceuticals buyer in Q3 2025 was EcoR1 Capital, an estimated $53.8M added.
- The largest Oric Pharmaceuticals seller in Q3 2025 was Frazier Life Sciences Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q3 2025.